Table 5.
Univariate and multivariate analysis of DFS in neoadjuvant chemotherapy or combined with immunotherapy group
| Characteristic | Univariate for DFS in neoadjuvant chemotherapy combined with immunotherapy group | Multivariate for DFS in neoadjuvant chemotherapy combined with immunotherapy group | Univariate for DFS in neoadjuvant chemotherapy group | Multivariate for DFS in neoadjuvant chemotherapy group | ||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|||||
| p-value | Odds ratio (95% CI) | p-value | Odds ratio (95% CI) | p-value | Odds ratio (95% CI) | p-value | Odds ratio (95% CI) | |
| Sex (male or female) | 0.284 | 1.579 (0.685–3.639) | - | - | 0.500 | 0.755 (0.334–1.708) | - | - |
|
| ||||||||
| Age (< 61 yr or ≥ 61 yr) | 0.524 | 0.756 (0.320–1.787) | - | - | 0.319 | 0.682 (0.322–1.448) | - | - |
|
| ||||||||
| Smoking history (smoker, ex-smoker or never smoker) | 0.336 | 1.532 (0.642–3.657) | - | - | 0.245 | 1.626 (0.717–3.689) | - | - |
|
| ||||||||
| Histology | 0.120 | - | - | - | 0.284 | - | - | - |
|
| ||||||||
| Squamous cell carcinomas | 0.247 | 2.413 (0.543–10.721) | 0.945 | 1.074 (0.140–8.219) | ||||
|
| ||||||||
| Adenocarcinoma | 0.061 | 4.232 (0.933–19.187) | - | - | 0.526 | 1.928 (0.254–14.638) | - | - |
|
| ||||||||
| Others | 1 | 1 | ||||||
|
| ||||||||
| Neoadjuvant therapy number of cycles (≤ 2 or > 2) | 0.587 | 0.807 (0.373–1.749) | - | - | 0.849 | 1.076 (0.507–2.283) | - | - |
|
| ||||||||
| N (N0 or N1–2) | 0.001 | 4.067 (1.739–9.512) | 0.038 | 1.645 (1.028–2.633) | 0.002 | 0.265 (0.113–0.621) | 0.212 | 0.549 (0.214–1.410) |
|
| ||||||||
| Baseline CEA (normal or high) | 0.010 | 3.108 (1.310–7.375) | 0.077 | 2.277 (0.915–5.663) | 0.336 | 1.433 (0.688–2.982) | - | - |
|
| ||||||||
| Preoperative CEA (normal or high) | 0.922 | 1.056 (0.355–3.141) | - | - | 0.374 | 0.714 (0.340–1.500) | - | - |
|
| ||||||||
| Baseline SCC (normal or high) | 0.143 | 0.496 (0.194–1.268) | - | - | 0.335 | 0.658 (0.281–1.542) | - | - |
|
| ||||||||
| Preoperative SCC (normal or high) | 0.808 | 0.882 (0.321–2.423) | - | - | 0.343 | 0.695 (0.327–1.476) | - | - |
|
| ||||||||
| Baseline TPSA (normal or high) | 0.491 | 0.711 (0.269–1.877) | - | - | 0.122 | 1.789 (0.856–3.741) | - | - |
|
| ||||||||
| Preoperative TPSA (normal or high) | 0.302 | 1.625 (0.647–4.082) | - | - | 0.425 | 1.396 (0.615–3.172) | - | - |
|
| ||||||||
| Baseline NLR (normal or high) | 0.004 | 4.264 (1.605–11.328) | 0.019 | 3.848 (1.252–11.827) | 0.008 | 4.337 (1.460–12.886) | 0.109 | 2.517 (0.813–7.791) |
|
| ||||||||
| Preoperative NLR (normal or high) | 0.026 | 5.131 (1.212–21.727) | 0.151 | 3.034 (0.668–13.776) | 0.004 | 4.741 (1.644–13.669) | 0.067 | 2.904 (0.926–9.102) |
CEA, carcinoembryonic antigen; CI, confidence interval; DFS, disease-free survival; NLR, neutrophil-to-lymphocyte ratio; SCC, squamous cell carcinoma antigen; TPSA, total prostate specific antigen.